The Technical Analyst
Soligenix Inc [SNGX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Soligenix Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.43% $0.400
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.21 mill |
| EPS: | -0.790 |
| P/E: | -0.510 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 10.52 mill |
| Avg Daily Volume: | 2.66 mill |
| RATING 2024-04-23 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.510 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.510 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.225 (-43.83%) $-0.175 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.349 - 0.451 ( +/- 12.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-15 | Zeldis Jerome B | Buy | 38 136 | Stock Option (Right to Buy) |
| 2023-12-15 | Parks Diane L. | Buy | 38 136 | Stock Option (Right to Buy) |
| 2023-12-15 | Rubin Robert J. | Buy | 38 136 | Stock Option (Right to Buy) |
| 2023-12-15 | Lapointe Anthony Gregg | Buy | 38 136 | Stock Option (Right to Buy) |
| 2023-12-08 | Donini Oreola | Buy | 90 000 | Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 96 transactions |
| Buy: 3 883 139 | Sell: 81 030 |
Forecast:
16:00 - $0.400
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.400
Forecast 2: 16:00 - $0.400
Forecast 3: 16:00 - $0.400
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.400 (-1.43% ) |
| Volume | 0.407 mill |
| Avg. Vol. | 2.66 mill |
| % of Avg. Vol | 15.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SNGX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:23 | buy | $0.650 | N/A | Active |
|---|
SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 08:30:00 - Press Release
Soligenix Announces Pricing Of $4.75 Million Public Offering
Princeton, n.j. , april 18, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) ("soligenix" or the "company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses.
2024-04-15 07:30:00 - Press Release
Fda Grants Soligenix Orphan Drug Designation For The Prevention And Post-exposure Prophylaxis Against Marburg Marburgvirus Infection
Provides marvax™ heat stable vaccine seven years of u.s. market exclusivity upon fda approval princeton, n.j. , april 15, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the office of orphan products development of the united states (u.s.) food and drug administration (fda) has granted orphan drug designation to the active ingredient in marvax™, the subunit protein vaccine of recombinantly expressed marburg marburgvirus (marv) glycoprotein, for "the prevention and post-exposure prophylaxis against marv infection.
2024-04-11 07:30:00 - Press Release
Fda Grants Soligenix Orphan Drug Designation For The Prevention And Post-exposure Prophylaxis Against Sudan Ebolavirus Infection
Provides suvax™ heat stable vaccine seven years of u.s. market exclusivity upon fda approval princeton, n.j. , april 11, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the office of orphan products development of the united states (u.s.) food and drug administration (fda) has granted orphan drug designation to the active ingredient in suvax™, the subunit protein vaccine of recombinantly expressed sudan ebolavirus (sudv) glycoprotein, for "the prevention and post-exposure prophylaxis against sudv infection.
2024-04-03 07:30:00 - Press Release
Soligenix Announces Agreement On The Design Of A Second Confirmatory Placebo-controlled Trial For Hybryte™ With The European Medicines Agency
Randomized study with 18 weeks continuous treatment expected to replicate and extend results from the first, statistically significant phase 3 study princeton, n.j. , april 3, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received agreement from the european medicines agency (ema) on the key design components of a confirmatory phase 3 placebo-controlled study evaluating the safety and efficacy of hybryte™ (synthetic hypericin) in the treatment of cutaneous t-cell lymphoma (ctcl) patients with early-stage disease.
2024-03-15 07:30:00 - Press Release
Soligenix Announces Recent Accomplishments And Year End 2023 Financial Results
Princeton, n.j. , march 15, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended december 31, 2023.
Latest News
2024-04-15 13:11:31 - Proactive Investors
Soligenix surges as MarVax vaccine secures Orphan Drug Designation from FDA
Soligenix (NASDAQ:SNGX) shares surged more than 44% after the biopharmaceutical company won Orphan Drug Designation from US regulators for the active ingredient in its MarVax vaccine for Marburg Marburgvirus (MARV), which causes Marburg Virus Disease. The designation specifically relates to the prevention and post-exposure prophylaxis against MARV infection.
2024-04-15 12:06:18 - InvestorPlace
Why Are Stocks Up Today?
Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected.
2024-04-15 11:18:30 - InvestorPlace
Why Is Soligenix (SNGX) Stock Up 58% Today?
Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Monday after getting an orphan drug designation for the active ingredient in MarVax. This comes from the Food and Drug Administration's (FDA) Office of Orphan Products Development.
2024-01-25 07:30:00 - PRNewsWire
Soligenix to Present at The Microcap Conference
PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at The Microcap Conference.
2024-01-02 09:19:50 - Proactive Investors
Soligenix shares rocket as bivalent vaccine shows preclinical efficacy
Soligenix (NASDAQ:SNGX) shares added almost 35% before the opening bell on Tuesday after it revealed its novel vaccine provided 100% protection against two deadly infections in non-human primate models. The company said that its single-vial bivalent vaccine demonstrated simultaneous protection against Sudan ebolavirus and Marburg Marburgvirus, two conditions for which there are no approved vaccines or therapeutics, in the preclinical evaluation.
2023-11-30 11:07:02 - InvestorPlace
Why Is Soligenix (SNGX) Stock Up 285% Today?
Soligenix (NASDAQ: SNGX ) stock is on the rise Thursday after the company got approval from the Food and Drug Administration for a Phase 2a clinical trial of SGX945. According to a press release from Soligenix, this clinical trial covers the safety and efficacy of SGX945 as a potential treatment for aphthous ulcers in Behçet's Disease.
2023-05-04 11:14:50 - Proactive Investors
Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study results
Soligenix (NASDAQ:SNGX) shares more than doubled on Thursday after the biopharmaceutical company announced positive results from a compatibility study of its investigational therapeutic HyBryte in cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. The company is developing and moving toward the potential commercialization of HyBryte (synthetic hypericin sodium) for the treatment of CTCL, a class of non-Hodgkin's lymphoma.
2023-02-14 10:44:50 - Proactive Investors
Soligenix stock slumps as cancer drug application is knocked back
Soligenix (NASDAQ:SNGX) slumped in Tuesday's early deals after revealing its cancer drug has been knocked back by the US Food and Drug Administration. The company, in a statement, told investors that it has received a Refusal to File (RTF) letter from the FDA for its HyBryte new drug application (NDA).
2023-01-19 07:30:00 - PRNewsWire
Soligenix Invited to Present at the Virtual Investor Summit Event
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Virtual Investor Summit on January 26, 2023.
2022-12-16 12:09:03 - InvestorPlace
7 Stocks to Add to Your 10x Watchlist
There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfolio.